Iterum Therapeutics Plc (ITRM) Stock Price, Quote & News

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 903 8354

Website: www.iterumtx.com

Address:

3 Dublin Landings, North Wall Quay, Dublin, Ireland

Twills08 Oct. 5 at 4:51 AM

$ITRM Remember, remember the 6th of October… buy your shares preH, and as many as possible imo. It’s time…

1 · Reply

DollerADay Oct. 5 at 2:21 AM

$ITRM I would love more than anything else to eat crow on Fish. The trade publications show Orlynvah to be more powerful than we imagine. From what I can see, we have 90 days of accumulation and the dilution proposal rejection may just be evil genius. Mon is the exact date as Durata. If Fish does this… his name is etched in gold alongside JC himself. CEOs with money seek glory, not additional pennies.

0 · Reply

DollerADay Oct. 5 at 2:11 AM

$ITRM I do believe it’s spoofing, including the wall on Friday. After deep thought, I’m starting to think Fish is a fucking genius and pitched the 80M dilution plan knowing it would be rejected. The stock is hammered down too low and the only way to get an extraordinary multiple in the short term is to bring the fork in the road to the vehicles. Now that the shareholders have spoken, everyone from PE can make a play on this game changing drug BP is toying with. We shall see soon.

2 · Reply

GatorMcKlusky Oct. 4 at 7:43 PM

$ITRM Whether we move Monday or not, does not matter to me one bit. I am of the firm belief this drug will outdo 1% market penetration, and will enter many foreign markets. Market cap will be seven to ten times where we are at now. The question is can it get done my Iterum as currently constructed? Answer is no. So there must be a buy out or financing. Non-dilutive financing. Either way, this stock rockets on either. The other catalyst would be simple confirmation of good scripts and the drug being adopted. That should give us a solid pop. As well, as bring in some better offers for the buyout. Take advantage of Sabby and HC Wainwright. Build a position. Why get mad at these jokers. Why look a gift horse in the mouth?

2 · Reply

richardxkxkTwits Oct. 4 at 7:18 PM

$ITRM why the shareholder did not approve so many proposals 😂

0 · Reply

Twills08 Oct. 4 at 5:59 PM

$ITRM October 6th……

1 · Reply

FishinAround Oct. 4 at 5:24 PM

$ITRM This is interesting, good for discussion if we can flesh it out a bit. I did dig in some and it looks like what @DollerADay was referencing; spoofing, not necessarily an imminent BO. Or just ATM. Sabby & HCW really seem to be fucking with this and have been though. I tried to do this but can’t because I’m working from an iPad most of the time and my laptop is at the office. If someone with an analytical mindset on here can use a PC or Mac to register on http://bookmap.com, where you start with a free trial, supposedly you will be able to see historical activity of these trades and glean something from what is going on, though we may need premium access to really see what we need to. Then please share so we can document it and I’ll add it to the SEC tip letter I have drafted, which I hopefully submit after a successful exit so they’ll take it more seriously. Let’s call this shit out if it stinks. Stretch ask but maybe @RossCameron_DayTrades can decipher something and help us out?

1 · Reply

JonDom22 Oct. 4 at 4:19 PM

$ITRM this stock must be like that old ex partner you can’t get over lol No matter how much they slag it off and critique it they always find time to come back and be involved in their life somehow lol I’ve played the same 4-5 swing trade stocks over this year, sarepta therapeutics been one of them where I made decent returns jumping in and out. But once my time is done with a stock it’s done, no point looking back in rear view mirror. Whereas with this stock the people who “hate and criticise” every aspect of it each day seem to be the ones most emotionally attached to it. Claim to have got out and still come back months later.

1 · Reply

gogo66so Oct. 4 at 3:03 PM

$ITRM New UTI Treatments on the Horizon At long last, providers will soon have three new treatments available for the treatment of uncomplicated UTIs. The only one presently available is Iterum Therapeutics’s Orlynvah (sulopenem etzadroxil and probenecid), which became the first and only oral penem antibiotic approved by the FDA https://www.mmitnetwork.com/thought-leadership/antibiotic-resistance-new-uti-treatments/

0 · Reply

PWstboy Oct. 4 at 8:32 AM

$ITRM The community here is still doing this lol The $100,000 lost to ITRM was restored to ASTS. It's such a waste of time I've been investing in Itrm for about five years. ITRM has a lot of problems. The concerns of numerous shareholders are not their concerns. They think of ITRM only as operating funds. Orlynvah? Medicine is very good. The problem is that only the medicine is good. The rest is the worst. This seems to be the limit for Penny Bio stock. I don't regret giving up ITRM, whether the stock price becomes $5 or $10. That's it for me, but I wish you all the success in investing in ITRM.

2 · Reply

Iterum Therapeutics Provides Business Update

Aug 20, 2025, 8:00 AM EDT - 6 weeks ago

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Aug 5, 2025, 4:58 PM EDT - 2 months ago

Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:00 AM EDT - 2 months ago

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 2, 2025, 4:30 PM EDT - 3 months ago

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 7:00 AM EDT - 3 months ago

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

Jun 25, 2025, 7:00 AM EDT - 3 months ago

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Iterum Therapeutics Announces Partnership for Commercialization Services

May 19, 2025, 7:00 AM EDT - 4 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note

May 13, 2025, 1:44 PM EDT - 5 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 30, 2025, 4:30 PM EDT - 5 months ago

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 14, 2025, 8:00 AM EDT - 6 months ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Feb 7, 2025, 10:20 AM EST - 8 months ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 7:00 AM EST - 8 months ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 31, 2025, 8:00 AM EST - 8 months ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Nov 21, 2024, 8:30 AM EST - 11 months ago

Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 14, 2024, 1:14 PM EST - 11 months ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:00 AM EST - 11 months ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 10:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)

Oct 28, 2024, 5:00 AM EDT - 1 year ago

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 11:03 AM EDT - 1 year ago

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024

Oct 9, 2024, 5:00 PM EDT - 1 year ago

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 6, 2024, 5:30 PM EDT - 1 year ago

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 31, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 13, 2024, 9:49 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Jan 30, 2024, 7:00 AM EST - 1 year ago

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Dec 4, 2023, 8:00 AM EST - 1 year ago

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Nov 14, 2023, 10:32 AM EST - 2 years ago

Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 7:00 AM EST - 2 years ago

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 8:30 AM EST - 2 years ago

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

Twills08 Oct. 5 at 4:51 AM

$ITRM Remember, remember the 6th of October… buy your shares preH, and as many as possible imo. It’s time…

1 · Reply

DollerADay Oct. 5 at 2:21 AM

0 · Reply

DollerADay Oct. 5 at 2:11 AM

2 · Reply

GatorMcKlusky Oct. 4 at 7:43 PM

2 · Reply

richardxkxkTwits Oct. 4 at 7:18 PM

$ITRM why the shareholder did not approve so many proposals 😂

0 · Reply

Twills08 Oct. 4 at 5:59 PM

$ITRM October 6th……

1 · Reply

FishinAround Oct. 4 at 5:24 PM

1 · Reply

JonDom22 Oct. 4 at 4:19 PM

1 · Reply

gogo66so Oct. 4 at 3:03 PM

0 · Reply

PWstboy Oct. 4 at 8:32 AM

2 · Reply

Amb8675309 Oct. 4 at 4:47 AM

$ITRM fishman will take an offer that, with a 2.5% bonus paid on the total BO price(meaning cash up front plus any milestones), makes him whole plus a nice return. $2-$4/share doesn’t math for him, so we wait- nice to hear someone’s accumulating using the dark pool

1 · Reply

Twills08 Oct. 4 at 3:58 AM

$ITRM Not an odd comment at all….this wall was what I am referring too. Please see attached. This wall was created by the MM. Give your google or chat gpt a buzz about Arca. This wall has allowed for consistent accumulation over the past weeks to months. It is hidden at times. Dark pool being utilized concurrently as well. A very frustrated retail has sold off bc of a lack of PR and share price movement. Thankfully, I neither get frustrated nor bored when a solid investment is identified. Catalyst is incoming. By incoming, I mean likely next week. Two weeks at the latest. Get in asap Monday AM imo.

1 · Reply

iambaron Oct. 4 at 3:54 AM

$ITRM Monday could be the the most smug crap I’ve ever seen… would be pretty funny tho

0 · Reply

TROYTIPTON Oct. 4 at 1:23 AM

$ITRM Still talking about "The Buyout".... HILARIOUS! Dreamers, schemers, conspiracy theorists and degenerate gamblers! 😅😅🤣😭😂

1 · Reply

Vic1990 Oct. 3 at 11:43 PM

$ITRM buy out?

3 · Reply

BobsOldMan Oct. 3 at 10:17 PM

$ITRM I finally sold this piece of crap after 4 years for a 93% loss.. Sick of looking at it. Feels good, now I'm deleting it off here. Goodluck everybody

5 · Reply

TROYTIPTON Oct. 3 at 9:50 PM

$ITRM Another week in the books, longs! Another Irish long-strokin'....enjoy!!! Y'all must love it! 😅🤣🤣😂😅

0 · Reply

Twills08 Oct. 3 at 9:28 PM

$ITRM I would like for you to kindly take a look at the AH wall currently holding this at $0.70. This isn’t dilution folks. They have accumulated. Held it in place, and now comes the fun part next week. Again, if you can buy, get in now imo.

2 · Reply

WhereistheSEC Oct. 3 at 8:55 PM

$ITRM ever get anywhere with this?

1 · Reply

look2theblue Oct. 3 at 8:31 PM

$ITRM On that we agree! My 4.3k shares of $PFE @ $23.41 are performing nicely. I expect $ITRM will do even better by the end of October. I think $PFE gets to $50 in time. $ITRM is good for a triple, possibly more. I'd love to see $PFE just buy $ITRM and announce the first penem antibiotic to be manufactured in the United States.

2 · Reply

Alder77 Oct. 3 at 8:03 PM

$ITRM another great day of dilution has ended, thanks Fishfuck

1 · Reply

Keepitmoving Oct. 3 at 7:44 PM

$ITRM so glad I have a bunch of LLY and PFE shares. 😅

0 · Reply

Market Cap	31.64M
Revenue (ttm)	0.00
Net Income (ttm)	-24.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-5.31

Volume	683,700
Avg Vol	827,940
Day's Range	N/A - N/A
Shares Out	47.17M
Stochastic %K	7%
Beta	3.24
Analysts	Strong Sell
Price Target	$7.00